BB,
<<I don't care about them, since I have no investment in those other companies. I purely wanted to point out that BVF has been manipulating this company's stock for years and routinely skimming profits.>
Link does work, but quote of two/three large blocks sale (NRGN) was wrong, imo. It does not belong to NRGN, it was from their other holdings. Last time that BVF sold NRGN is in 1999.
Anyway, BVF did adapt buy and take profit (whenever is possible) strategy after 2000-bubble. The strategy that many bio-freaks (hare at SI) are using to *stay alive*. So, I do not think that BVF are manipulating stock, but they will sell if they see chance for good profit.
Also, BVF investment field is neuro-bios, and right now there are no many bios that can attract investor’s attention. They are buyers when other founds are bailing out, large blocks acquisition at fix price.
<<April. IMO, they either know something about potential research developments or are potentially looking to acquire NRGN. >>
What Lampert knows I do not know, but they are not in to acquire NRGN. NRGN has two were interesting program, and if only one work out we are here for 10X return in time.
"Gdje ima dima ima i vatre!"
Where is smoke there is a chance for fire!
Personally, I think that NRGN VL-1 receptor antagonist (If you are following company and know bit about their programs?) candidate/program may generate some positive development in near (let say 3-6 months) future.
Miljenko |
